Finally, our results, including those on multiple myeloma cells lacking DDI2, support the idea that inhibition of DDI2 protease might have clinical benefit in cancer therapy, alone or in conjunction with proteasome inhibition. This evidence concerns the gene DDI2 and AL amyloidosis.